These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
382 related articles for article (PubMed ID: 30416011)
1. SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML. DiNardo CD; Stein EM Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):769-772. PubMed ID: 30416011 [TBL] [Abstract][Full Text] [Related]
2. IDH Inhibitors in AML-Promise and Pitfalls. McMurry H; Fletcher L; Traer E Curr Hematol Malig Rep; 2021 Apr; 16(2):207-217. PubMed ID: 33939107 [TBL] [Abstract][Full Text] [Related]
3. Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120. Birendra KC; DiNardo CD Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):460-5. PubMed ID: 27245312 [TBL] [Abstract][Full Text] [Related]
4. Targeting the Amaya ML; Pollyea DA Clin Cancer Res; 2018 Oct; 24(20):4931-4936. PubMed ID: 29769206 [TBL] [Abstract][Full Text] [Related]
5. Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation. Becker JS; Fathi AT Curr Cancer Drug Targets; 2020; 20(7):490-500. PubMed ID: 32329690 [TBL] [Abstract][Full Text] [Related]
6. IDH1/2 Mutations in Cancer Stem Cells and Their Implications for Differentiation Therapy. Molenaar RJ; Wilmink JW J Histochem Cytochem; 2022 Jan; 70(1):83-97. PubMed ID: 34967233 [TBL] [Abstract][Full Text] [Related]
7. Updates on DNA methylation modifiers in acute myeloid leukemia. Contieri B; Duarte BKL; Lazarini M Ann Hematol; 2020 Apr; 99(4):693-701. PubMed ID: 32025842 [TBL] [Abstract][Full Text] [Related]
8. Clinical Implications of Isocitrate Dehydrogenase Mutations and Targeted Treatment of Acute Myeloid Leukemia with Mutant Isocitrate Dehydrogenase Inhibitors-Recent Advances, Challenges and Future Prospects. Kowalczyk A; Zarychta J; Lejman M; Latoch E; Zawitkowska J Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063158 [TBL] [Abstract][Full Text] [Related]
9. Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia. Cortes JE Expert Rev Hematol; 2024 Jun; 17(6):211-221. PubMed ID: 38747392 [TBL] [Abstract][Full Text] [Related]
10. Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness. Liu ACH; Cathelin S; Yang Y; Dai DL; Ayyathan DM; Hosseini M; Minden MD; Tierens A; Chan SM Cancer Res; 2022 Dec; 82(23):4325-4339. PubMed ID: 36150062 [TBL] [Abstract][Full Text] [Related]
11. All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells. Kim Y; Jeung HK; Cheong JW; Song J; Bae SH; Lee JI; Min YH Yonsei Med J; 2020 Sep; 61(9):762-773. PubMed ID: 32882760 [TBL] [Abstract][Full Text] [Related]